LENZ
LENZ Therapeutics, Inc.
1W: -22.6%
1M: -29.2%
3M: -48.5%
YTD: -43.3%
1Y: -66.0%
$8.70
-0.37 (-4.08%)
After Hours: $7.62 (-1.08, -12.41%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$283.8M
52W Range8.99-50.4
Volume1,424,097
Avg Volume953,693
Beta0.51
Dividend$7.21
Analyst Ratings
Company Info
CEOEvert Schimmelpennink
Employees6
SectorHealthcare
IndustryBiotechnology
IPO Date2024-03-22
Websitelenz-tx.com
445 Marine View Avenue
Solana Beach, CA 92014
US
Solana Beach, CA 92014
US
(858) 925-7000
About LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Latest News
Lenz outlines 2026 acceleration strategy while expanding VIZZ sales force to 117 reps
Why Lenz Therapeutics Stock Crashed Today
LENZ Therapeutics, Inc. (LENZ) Reports Q4 Loss, Misses Revenue Estimates
LENZ Therapeutics GAAP EPS of -$1.16 misses by $0.26, revenue of $1.59M misses by $1.5M
LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Olsson Shawn | A-Award | 84,200 | $16.00 | 2026-01-02 |
| Olsson Shawn | A-Award | 14,000 | — | 2026-01-02 |
| Odrich Marc | A-Award | 84,200 | $16.00 | 2026-01-02 |
| Odrich Marc | A-Award | 14,000 | — | 2026-01-02 |
| Chevallard Daniel R. | A-Award | 84,200 | $16.00 | 2026-01-02 |